ISPE 2026: The changing landscape of pegfilgrastim: Real-world adoption and switching behavior of biosimilars

Authors: Jared Kern ⊕, Truveta, Inc, Bellevue, WA, Vidya Venkataraman, PhD ⊕, Truveta, Inc, Bellevue, WA, Esther Kim, PhD ⊕, Truveta, Inc, Bellevue, WA, Joud Roufael, MPH ⊕, Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕, Truveta, Inc, Bellevue, WA, Amy Wu ⊕, Truveta, Inc, Bellevue, WA, Sarah Eng, MPH ⊕, Truveta, Inc, Bellevue, WA, Puja Rao, MPH ⊕, Truveta, Inc, Bellevue, WA, Mantas Dmukauskas, PhD ⊕ Truveta, Inc, Bellevue, WA, By 2025, two-thirds of patients receiving pegfilgrastim were treated exclusively with biosimilars, while 30% received Neulasta only. Biosimilar uptake was similar acros